StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Johnson & Johnson (JNJ) Talc-Related Risk Much Less Than Market Thinks - Cowen
February 28, 2019 12:06 PM
Cowen analyst Joshua Jennings weighed in on Johnson & Johnson (NYSE: JNJ) after the company restarted production of cosmetic talk ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Johnson & Johnson to Participate in Barclays Global Healthcare Conference
February 28, 2019 11:56 AM
India drug regulator finds no asbestos in Johnson & Johnson (JNJ) talc - Reuters
February 28, 2019 7:31 AM
MeiraGTx Holdings plc (MGTX) PT Raised to $40 at Chardan Capital Markets; 3rd Investment by J&J
February 27, 2019 11:45 AM
Janssen (JNJ) Announces FDA Approval of Novel TREMFYA One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
February 27, 2019 7:47 AM
Grassley, Wyden Deliver Opening Remarks in Drug Pricing Hearing - Bloomberg
February 26, 2019 10:40 AM
